Exploring a Novel Approach to Spare Classic Chemotherapy in HER2-Low, ER-Positive Breast Cancer Based on Trastuzumab Deruxtecan Combined with Endocrine Therapy.

Autor: Scafuri, Luca, Buonerba, Carlo, Di Lauro, Vincenzo, Tortora, Vincenzo, Cascella, Marco, Liguori, Luigi, Sciarra, Antonella, Sabbatino, Francesco, Diana, Anna, Marra, Antonio, Tarantino, Paolo, Trapani, Dario, Giuliano, Mario, Arpino, Grazia, Curigliano, Giuseppe, Di Lorenzo, Giuseppe
Předmět:
Zdroj: Oncology & Therapy; Sep2024, Vol. 12 Issue 3, p363-373, 11p
Abstrakt: Background: Breast cancer presents diverse molecular subtypes affecting treatment strategies. Human epidermal growth factor receptor 2 (HER2)-low, hormone receptor-positive (HR+) breast cancer poses a challenge due to limited targeted therapies. Current neoadjuvant treatment primarily utilizes chemotherapy, with conflicting results regarding efficacy in patients with HER2-low breast cancer. Trastuzumab deruxtecan (T-DXd) shows promise in HER2-low metastatic disease, and preliminary evidence suggests synergy with endocrine therapy. Objective: This editorial explores the hypothesis that neoadjuvant T-DXd with or without endocrine therapy offers efficacy in the clinical management of HR+/HER2-low breast cancer. Methods: We propose a phase II study with two treatment arms: T-DXd + letrozole and T-DXd alone. The primary endpoint is the radiological complete response rate. Secondary endpoints include pathological complete response rate, safety, event-free survival, and overall survival. Exploratory analyses will compare the arms to identify potential for optimizing treatment efficacy and minimizing side effects. Conclusions: This study design allows for initial assessment of T-DXd with or without endocrine therapy in the treatment of HER2-low breast cancer. The findings may pave the way for personalized treatment strategies and inform future research, potentially leading to a chemotherapy-sparing approach. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: